First-in-class therapeutics for autoimmune disorders
Developing the first disease-modifying treatment for severe autoimmune disorders.
About Us
We develop first-in-class biologics for several underserved autoimmune conditions. Our therapeutic approach aims to preserve and re-establish organ cell function, transforming the treatment paradigm for intractable autoimmune diseases.
Pathway
We target the IGFBP3/TMEM219 axis, a novel pathway involved in cell apoptosis in the gut, pancreas and other organs which plays a key role in the development of Type 1 Diabetes and Inflammatory Bowel Disease.
Pipeline
Our discovery engine delivers libraries of monoclonal antibodies (mAbs) and fusion proteins that target the IGFBP3/TMEM219 pathway. Our lead program Ent001 is expected to enter Phase I clinical trials by 2021.
Circulating hormones control gut stem cell in diabetes (Featuring Paolo Fiorina, Enthera’s CSO)
